Institution
Loma Linda University
Education•Loma Linda, California, United States•
About: Loma Linda University is a education organization based out in Loma Linda, California, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 9220 authors who have published 13485 publications receiving 447094 citations. The organization is also known as: University of Loma Linda.
Topics: Population, Medicine, Poison control, Transplantation, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In a nationally representative cohort of privately insured persons, AC enrollees were disproportionately sicker at presentation, were admitted and readmitted more often, and incurred nearly double the per‐person health care costs compared to those with non‐AC.
149 citations
••
TL;DR: In this paper, the authors designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with ALS and to assess safety and tolerability.
Abstract: We designed a phase II trial to evaluate the efficacy of gabapentin in slowing the rate of decline in muscle strength of patients with amyotrophic lateral sclerosis (ALS) and to assess safety and tolerability. Gabapentin (800 mg) or placebo was administered t.i.d. in a randomized, double-blinded, placebo-controlled, trial for 6 months. We enrolled 152 patients at eight sites in the United States. The primary outcome measure was the slope of the arm megascore, the average maximum voluntary isometric strength from eight arm muscles standardized against a reference ALS population. A secondary outcome measure was forced vital capacity. Slopes of arm megascores for patients on gabapentin were compared with slopes of those taking placebo using a two-way ANOVA. We observed a nonstatistically significant trend (p = 0.057-0.08) toward slower decline of arm strength in patients taking gabapentin compared with those taking placebo (mean difference 24%, median 37%). We observed no treatment effect on forced vital capacity. Gabapentin was well tolerated by patients with ALS. These results suggest that further studies of gabapentin in ALS are warranted.
149 citations
••
TL;DR: The primitive component of the MG‐PNET arises within a pre‐existing MG, most often a secondary glioblastoma, and may represent a metaplastic process or expansion of a tumor stem/progenitor cell clone; often shows histologic anaplasia and N‐ myc (or c‐myc) amplification; has the capacity to seed the CSF; and may respond to platinum‐based chemotherapy regimens.
Abstract: Central nervous system neoplasms with combined features of malignant glioma and primitive neuroectodermal tumor (MG-PNET) are rare, poorly characterized, and pose diagnostic as well as treatment dilemmas. We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years). The PNET-like component consisted of sharply demarcated hypercellular nodules with evidence of neuronal differentiation. Anaplasia, as seen in medulloblastomas, was noted in 70%. Within the primitive element, N-myc or c-myc gene amplifications were seen in 43%. In contrast, glioma-associated alterations involved both components, 10q loss (50%) being most common. Therapy included radiation (78%), temozolomide (63%) and platinum-based chemotherapy (31%). Cerebrospinal fluid (CSF) dissemination developed in eight patients, with response to PNET-like therapy occurring in at least three. At last follow-up, 27 patients died, their median survival being 9.1 months. We conclude that the primitive component of the MG-PNET: (i) arises within a pre-existing MG, most often a secondary glioblastoma; (ii) may represent a metaplastic process or expansion of a tumor stem/progenitor cell clone; (iii) often shows histologic anaplasia and N-myc (or c-myc) amplification; (iv) has the capacity to seed the CSF; and (v) may respond to platinum-based chemotherapy regimens.
149 citations
••
TL;DR: Factors associated with maternal obesity in well-controlled gestational diabetes mellitus may be more significant than glucose control in the development of large-for-gestational-age infants.
149 citations
••
TL;DR: It is concluded that a syndrome of reversible parkinsonism and cognitive impairment may develop insidiously in patients who have been treated with valproate for more than 12 months.
Abstract: Following our initial report of the insidious development of reversible, valproate-induced hearing, motor, and cognitive dysfunction in two patients, we evaluated 36 patients in an epilepsy clinic who had been taking therapeutic levels of valproate for at least 12 months; 29 of these patients were examined according to a prospective protocol. We observed varying degrees of parkinsonism and cognitive impairment, from none to severe. Discontinuation of valproate in 32 affected patients led to subjective and objective improvement on follow-up testing at least 3 months later. Improvement was greatest in patients who were affected most. We conclude that a syndrome of reversible parkinsonism and cognitive impairment may develop insidiously in patients who have been treated with valproate for more than 12 months. The association with valproate may be overlooked due to the insidious onset.
149 citations
Authors
Showing all 9287 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bruce L. Miller | 163 | 1153 | 115975 |
Jonathan I. Epstein | 138 | 1121 | 80975 |
Tony L. Yaksh | 123 | 806 | 60898 |
David M. Livingston | 118 | 312 | 58142 |
William B. Isaacs | 117 | 521 | 58187 |
Alan W. Partin | 111 | 710 | 54213 |
David N. Herndon | 108 | 1227 | 54888 |
Edward R. Laws | 105 | 722 | 39822 |
David C. Bellinger | 98 | 452 | 35449 |
Pedram Argani | 97 | 372 | 35607 |
Michael W. Steffes | 96 | 341 | 43260 |
Gary K. Steinberg | 94 | 529 | 31259 |
Michael S. Gazzaniga | 92 | 372 | 35305 |
David J. Baylink | 90 | 425 | 29109 |
Jesse B. Jupiter | 90 | 543 | 26480 |